Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Neogene Therapeutics

company

About

Neogene Therapeutics is a biotech company providing cancer patients with T cell therapies targeting mutated proteins called neo-antigens.

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$15M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
101 - 250
Operating Status
Active
Legal Name
Neogene Therapeutics, Inc.

Neogene Therapeutics provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens. The company is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.

Neogene's platform allows for the isolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The company’s proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$125M
Neogene Therapeutics has raised a total of $125M in funding over 2 rounds. Their latest funding was raised on Sep 14, 2020 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 14, 2020 Series A $110M 8 EcoR1 Capital
Jeito Capital
Syncona Partners LLP
Detail
May 23, 2019 Series Unknown $15M Detail

Investors

Number of Lead Investors
Number of Investors
3
8
Neogene Therapeutics is funded by 8 investors. EcoR1 Capital and Jeito Capital are the most recent investors.
Investor Name Lead Investor Funding Round
EcoR1 Capital Yes Series A
Jeito Capital Yes Series A
Syncona Partners LLP Yes Series A
Polaris Partners Series A
Pontifax Series A
TPG Series A
Two River Series A
Vida Ventures Series A

Employee Profiles

Number of Employee Profiles
6
Neogene Therapeutics has 6 current employee profiles, including Executive Carsten Linnemann
Executive
Executive
Executive
Employee
Executive